Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -5.89% is 81% above its 5-year average of -31.50%, near the high end of its 5-year range (-106.10%–16.89%).
As of the fiscal period ended Wednesday, December 31, 2025. 54.83% above its 12-month average of -13.04%.
Annual fiscal-year return on equity; no daily interpolation. Historical series through 2025-12-31.
RETURN ON EQUITY (ROE)
-5.89%
RETURN ON EQUITY (ROE) AVG TTM
-13.04%
RETURN ON EQUITY (ROE) AVG 3Y
-24.95%
RETURN ON EQUITY (ROE) AVG 5Y
-31.50%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+54.83%
CURRENT VS 3Y AVG
+76.40%
CURRENT VS 5Y AVG
+81.30%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
+85.98%
vs the sector median at left
Niki BioSolutions, Inc.
Market Cap
$381940.00
Return on Equity (ROE)
-5.89%
TTM Avg
-13.04%
3Y Avg
-24.95%
5Y Avg
-31.50%
Market Cap
$380715.00
Return on Equity (ROE)
-66.30%
TTM Avg
-86.35%
3Y Avg
-89.49%
5Y Avg
-12.24%
Market Cap
$490141.00
Return on Equity (ROE)
-68.17%
TTM Avg
-111.11%
3Y Avg
-104.52%
5Y Avg
-88.82%
Market Cap
$242924.00
Return on Equity (ROE)
-287.31%
TTM Avg
-182.19%
3Y Avg
-117.96%
5Y Avg
-131.39%
Market Cap
$524770.00
Return on Equity (ROE)
N/A
TTM Avg
617.94%
3Y Avg
178.97%
5Y Avg
105.84%
Market Cap
$559702.00
Return on Equity (ROE)
-66.26%
TTM Avg
77.79%
3Y Avg
-17.48%
5Y Avg
-22.53%
Market Cap
$108729.00
Return on Equity (ROE)
-31722.73%
TTM Avg
-22.71%
3Y Avg
4.16%
5Y Avg
21.87%
Market Cap
$97282.00
Return on Equity (ROE)
N/A
TTM Avg
-12.94%
3Y Avg
110.91%
5Y Avg
74.52%
Market Cap
$664522.00
Return on Equity (ROE)
6.58%
TTM Avg
129.48%
3Y Avg
106.12%
5Y Avg
-3462.32%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Niki BioSolutions, Inc. (NIKI) | $381940.00 | -5.89% | -13.04% | -24.95% | -31.50% |
| Virax Biolabs Group Limited (VRAX)vs › | $380715.00 | -66.30% | -86.35% | -89.49% | -12.24% |
| XORTX Therapeutics Inc. (XRTX)vs › | $490141.00 | -68.17% | -111.11% | -104.52% | -88.82% |
| SciSparc Ltd. (SPRC)vs › | $242924.00 | -287.31% | -182.19% | -117.96% | -131.39% |
| VivoSim Labs, Inc. (VIVS)vs › | $524770.00 | N/A | 617.94% | 178.97% | 105.84% |
| HCW Biologics Inc. (HCWB)vs › | $559702.00 | -66.26% | 77.79% | -17.48% | -22.53% |
| Silexion Therapeutics Ltd. (SLXN)vs › | $108729.00 | -31722.73% | -22.71% | 4.16% | 21.87% |
| Psyence Biomedical Ltd. (PBM)vs › | $97282.00 | N/A | -12.94% | 110.91% | 74.52% |
| CDT Equity Inc. (CDT)vs › | $664522.00 | 6.58% | 129.48% | 106.12% | -3462.32% |
| PRF Technologies Ltd. (PRFX)vs › | $72519.00 | -56.04% | -428.20% | -266.31% | -188.29% |
ROE
-5.9%
ROA
-7.3%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | -5.89% |
| 2024-12-31 | -20.19% |
| 2023-12-31 | -11.37% |
| 2022-12-31 | -62.37% |
| 2021-12-31 | -106.10% |
| 2020-12-31 | 16.89% |
| 2019-12-31 | -114.22% |
| 2018-12-31 | -44.79% |
| 2017-12-31 | -8.42% |
